Sector News

Big pharma: dealing with fewer biotech targets

January 4, 2016
Life sciences

The torrid pace of consolidation among drugmakers is bound to slow at some point. But that doesn’t mean deal bankers and lawyers will be idle in 2016.

There have been more than 2,000 announced deals over the past two years within the pharmaceuticals and biotechnology sectors world-wide, according to Dealogic, for a total consideration north of $750 billion. This wave has arisen as big pharmaceutical companies hunted for promising biotechs as a way to conjure growth.

The pace isn’t likely sustainable. Consider that the second-most prolific two-year period of biopharma deals, in 2008 and 2009, yielded less than half the recent deal volume.

But even if volume falters, prices for targets might continue to rise. And that holds risk for shareholders in big pharma companies on the prowl, of which there are many.

For instance, Shire continues its pursuit of Baxalta, which sports a market value of $27 billion. Amgen has said it is on the hunt for a purchase of up to $10 billion. Gilead Sciences, meanwhile, sports a pile of cash and equivalents above $25 billion as it grapples with the maturation of its juggernaut hepatitis C franchise, which accounts for more than half of revenue in the 12 months ended Sept. 30.

And hunters need deals that are big enough to move the needle on growth. There are fewer of those around. For example, there are now just seven companies within the Nasdaq Biotechnology Index that sport a market value between $5 billion and $10 billion, according to FactSet. Over the past two years, 14 deals have been struck for a total transaction value in that range, winnowing the number of such candidates.

As the number of big targets dwindles, along with a multiyear biotech bull market, prices are rising. Earlier in December, AstraZeneca announced a $4 billion deal to acquire a 55% stake in closely held Acerta Pharma, a clinical stage biotech.

Meanwhile, the macroeconomic environment is still supportive of consolidation. Corporate borrowing costs remain low, despite the Federal Reserve’s move to raise interest rates for the first time in a decade. Economic growth is tepid, and the biggest pharma companies still face a future of slow growth.

So buyers will probably have to be prepared to pay more or be willing to take chances on products in earlier stages of development. That is good news for investors in potential prey.

But there is a clear danger for big-pharma shareholders: As deals get pricier, it will be tougher to add value.

By Charley Grant

Source: Wall Street Journal

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.